Monopar Therapeutics (MNPR) Competitors

Immatics (NASDAQ:IMTX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Does the media prefer IMTX or MNPR?

In the previous week, Immatics had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 7 mentions for Immatics and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 1.60 beat Immatics' score of 1.13 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts recommend IMTX or MNPR?

Immatics presently has a consensus target price of $14.67, suggesting a potential upside of 140.44%. Monopar Therapeutics has a consensus target price of $55.33, suggesting a potential upside of 53.38%. Given Immatics' stronger consensus rating and higher probable upside, equities analysts plainly believe Immatics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Monopar Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Do institutionals & insiders have more ownership in IMTX or MNPR?

64.4% of Immatics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 3.3% of Immatics shares are held by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has preferable earnings & valuation, IMTX or MNPR?

Monopar Therapeutics has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$144.15M	5.14	-$104.98M	-$0.17	-35.88
Monopar Therapeutics	N/A	N/A	-$8.40M	-$3.48	-10.37

Does the MarketBeat Community prefer IMTX or MNPR?

Monopar Therapeutics received 14 more outperform votes than Immatics when rated by MarketBeat users. However, 74.42% of users gave Immatics an outperform vote while only 71.88% of users gave Monopar Therapeutics an outperform vote.

Company	Underperform	Outperform
Immatics	Outperform Votes 32 74.42%	Underperform Votes 11 25.58%
Monopar Therapeutics	Outperform Votes 46 71.88%	Underperform Votes 18 28.13%

Is IMTX or MNPR more profitable?

Monopar Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -47.94%. Immatics' return on equity of -15.90% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-47.94%	-15.90%	-9.38%
Monopar Therapeutics	N/A	-107.21%	-87.57%

Which has more risk and volatility, IMTX or MNPR?

Immatics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.

Summary

Immatics beats Monopar Therapeutics on 12 of the 18 factors compared between the two stocks.